Dr. Reddy’s Launches India’s First DCGI-Approved Semaglutide Injection ‘Obeda®’ for Type 2 Diabetes
Dr. Reddy’s Laboratories Ltd. has announced the launch of its injectable semaglutide under the brand name Obeda®, marking an important step in expanding access to advanced GLP-1 receptor agonist–based therapy for the management of type 2 diabetes in India. The company is the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company’s Day-1 entry into the segment upon patent expiry, demonstrating its readiness to serve unmet patient needs in India. The Obeda® injection has shown non-inferior efficacy and similar safety to the innovator drug in a head-to-head Phase-III clinical study. It is available in 2 mg and 4 mg strengths and comes in a pre-filled, disposable format for subcutaneous, once-a-week administration with a user-friendly pen device.
Key Highlights
- Dr. Reddy’s launches India’s first DCGI-approved Semaglutide injection ‘Obeda®’ for Type 2 Diabetes
- Obeda® has shown non-inferior efficacy and similar safety to the innovator drug in a head-to-head Phase-III clinical study
- Dr. Reddy’s is the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide
- Obeda® is available in 2 mg and 4 mg strengths and comes in a pre-filled, disposable format for subcutaneous, once-a-week administration with a user-friendly pen device
- Dr. Reddy’s aims to introduce generic semaglutide in several countries, subject to regulatory approval